A clinical-stage biotechnology company in immunotherapy

Focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases.

Our latest press release

Read more

17/01/2022

OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

Download

To receive OSE Immunotherapeutics’ latest news